Abstract
Chronic pain, defined as pain that persists for greater than three months, is a common, understudied condition that affect an estimated 20-30% of the population. Despite a high prevalence and distressing physical and psychological symptoms, research is lacking in appropriate long-term pharmaceutical treatment for chronic pain, and chronic pain persists at high rates even with intervention. Recent genome-wide association studies (GWAS) of chronic pain indicate that chronic pain can be studied as a distinct neuropsychiatric illness with genetic risk. Here we develop a genetics-informed framework to identify new drug repurposing candidates for chronic pain. We first use a functional genomics approach to drug repurposing, called signature mapping, to identify drug repurposing candidates for chronic pain. In a signature mapping analysis, the transcriptomic effects of disease and drug perturbations are compared, and drugs with opposite effects on gene expression as the disease are nominated as therapeutic candidates. Then we further investigate therapeutic avenues through causal inference using two-sample Mendelian randomization analysis, leveraging GWAS of chronic pain and GWAS of medication use across 23 drug classes. This approach, driven by information from genome- and transcriptome-wide associations with chronic pain, can yield additional insights beyond the single receptor- or molecule-level drug discovery investigation in traditional drug development pipelines.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
LMH acknowledges funding from NIMH (R01MH124839, R01MH118278, R01MH125938, RM1MH132648, R01MH136149), NIEHS (R01ES033630), and the Department of Defense (TP220451). CS acknowledges funding from NIH (F30MH132324).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
